化疗序贯自体造血干细胞移植治疗淋巴瘤的疗效评价及影响因素分析

目的:探讨化疗序贯自体造血干细胞移植(auto-HSCT)对淋巴瘤患者的疗效及影响因素.方法:回顾性分析2015年09月至2020年12月于我科接受大剂量化疗(HDC)序贯自体外周血造血干细胞移植治疗的患者,并进行疗效及不良反应评价.结果:40例患者,其中非霍奇金淋巴瘤34例,霍奇金淋巴瘤6例;男性27例,女性13例,...

Efficacy evaluation and influencing factors of autologous hematopoietic stem cell transplantation following chemotherapy in the treatment of lymphoma

Objective:To explore the efficacy and influencing factors of autologous hematopoietic stem cell transplantation(auto-HSCT)following chemotherapy in the treatment of lymphoma.Methods:Retrospective analysis was made in lymphoma patients treated with high-dose chemotherapy(HDC)and sequential auto-HSCT in our department from Sep.2015 to Dec.2020,the efficacy and adverse reactions were evaluated.Results:40 patients,including 34 cases of non-Hodgkin lymphoma and 6 cases of Hodgkin lymphoma;There were 27 males and 13 females,with a median age of 44(15-65)years.Except for 2 patients who died early after auto-HSCT,the remaining 38 patients had hematopoietic reconstruction.The median platelet engraftment time was 10(6~15)days,median neutrophil engraftment time was 9(7~14)days.25 patients(62.5%)had complete remission before transplantation,9 cases(22.5%)had partial remission,6 cases(15%)had no remission.The early transplantation related mortality(TRM)occurred in 2 cases(5%).The median follow-up time was 27(0.2~64)months.1 year and 3 years overall survival(OS)rates were 92.3%and 85.4%.1 year and 3 years progression-free survival(PFS)rates were 81.6%and 66.9%.Whether achieving complete remission(CR)before transplantation was major risk factor affecting the prognosis of lymphoma patients with auto-HSCT(P<0.05),and an independent risk factor affecting PFS(P<0.05).Conclusion:HDC followed by auto-HSCT is a safe and effective treatment for lymphoma.Achieving CR before transplantation is beneficial for the therapeutic outcome.